Microneedle-based transdermal co-delivery of chondroitin sulfate and stem cell-derived exosomes for RA treatment
Van Dat Bui – Researcher, Vinmec International Hosptial, Vin University; Jueun Jeon – Postdoctoral researcher, Massachusetts General Hospital, Harvard Medical School; Jae Hyung Park – Professor, School of Chemical Engineering, Sungkyunkwan University
Student Sungkyunkwan university, Republic of Korea
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease that requires long-term immunomodulation, yet systemic therapies are frequently limited due to adverse effects. While stem cell-derived exosomes (EXO) have emerged as promising therapeutic agents, their efficient and practical delivery remains challenging. Here, we report the development of a microneedle (MN) platform that enables transdermal co-delivery of chondroitin sulfate (CS) and EXO, offering a localized and minimally invasive strategy for RA therapy.
Learning Objectives:
Understand the concept of dissolving microneedle therapy.
Explain the key characterization and in vitro evaluation methods used in this study.
Evaluate the therapeutic efficacy and safety of transdermal co-delivery of EXO and CS in RA animal model.
